Hong Kong Regen Medtech Limited (HKRM) is a stem cell biotechnology company dedicated to developing stem cell therapy for intractable diseases. Through harnessing the therapeutic potential of stem cells, HKRM is developing new medicine targeting degenerative and immunological diseases. HKRM engineered stem cell manipulation and differentiation platform mimicking native developmental niches to generate high-quality cell therapy products.
香港再生醫學有限公司 (Hong Kong Regen Medtech Limited “HKRM”) 於2019年成立並落戶於香港科學園的一間幹細胞生物科技初創公司，致力透過幹細胞的技術實現健康和長壽的願景。HKRM 旨在通過建立一個融合平台，利用幹細胞的新技術及治療潛力來開發、製造和提供跨平台治療的幹細胞產品。
Company Details
- Founded
- -
- Address
- Hong Kong Science Park, Hong Kong,hong Kong
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.hkrmltd.com
- HQ
- Hong Kong
Hong Kong Regen Medtech Limited Questions
Hong Kong Regen Medtech Limited's website is http://www.hkrmltd.com
Hong Kong Regen Medtech Limited's LinkedIn profile is https://hk.linkedin.com/company/hkrmltd
Hong Kong Regen Medtech Limited's industry is
Biotechnology Research
Hong Kong Regen Medtech Limited's top competitors are
Vita Green,
Xellera Therapeutics,
Cordlife (Hong Kong) Limited,
Act Genomics,
Novoheart,
Center For Neuromusculoskeletal Restorative Medicine Limited,
Medera Inc.,
Phase Scientific International Limited,
Advanced Biomedical Instrumentation Centre,
Mononuclear Therapeutics Limited.
Hong Kong Regen Medtech Limited's categories are Biotechnology Research
Hong Kong Regen Medtech Limited's founding year is 2019
